Ntla stock forecast.

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.41. This compares to loss of $1.96 per share a year ago.Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceDosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to ...Nov 29, 2023 · See the latest Intellia Therapeutics Inc stock price (NTLA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. As for NTLA-2002, the company plans to kick off the Phase 2 segment of the ongoing Phase 1/2 study during the first half of the year. An IND to get U.S. sites included in the Phase 2 study of NTLA ...

The current Intellia Therapeutics [ NTLA] share price is $28.76. The Score for NTLA is 45, which is 10% below its historic median score of 50, and infers higher risk than normal. NTLA is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.Intellia Therapeutics will start 2025 at $39.50, then soar to $40.96 within the first six months of the year and finish 2025 at $47.84. That means +51% from today. Intellia Therapeutics Stock Forecast 2030-2034. In this period, the Intellia Therapeutics price would rise from $91.85 to $115.11, which is +25%.

Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis.Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis.

NTLA Revenue (Quarterly) data by YCharts. More than $1 billion in cash At the same time, though, Intellia reported $1.1 billion in cash during its most recent earnings call and about $200 million ...It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...According to the National Snow & Ice Data Center, blizzard prediction relies on modeling weather systems, as well as predicting temperatures. The heavy snowfall that blizzards create can be hard to predict in advance.Verve Therapeutics Inc () Stock Market info Recommendations: Buy or sell Verve Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Verve Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Verve Therapeutics's VERV shares and potentially its …Intellia Therapeutics has recently been granted FDA clearance to include the United States in the global Phase 2 portion of its Phase 1/2 study for NTLA-2002. This is a significant milestone for ...

While many growth stocks have rallied in 2023, Exelixis stock has moved up and down since the start of the year. ... NTLA-2002 could be a game-changing treatment for hereditary angiodema (HAE), a ...

The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is anticipated to initiate by year-end 2023. "The FDA clearance of the NTLA-2001 IND application allows us to initiate a pivotal Phase 3 trial in the United States, marking the first in vivo CRISPR-based candidate to begin late-stage clinical development.

NTLA stock's Price/Earning ratio is 115.00. Our analysis grades NTLA stock's Price / Earning ratio at F. This means that NTLA stock's Price/Earning ratio is above 92% of the stocks in the Biotechnology sector in the NSD exchange. Based on this NTLA may be a overvalued for its sector.The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00. The median estimate represents a +137.08% increase from the last price of 30.37. The current consensus among 27 polled investment analysts is to Buy stock in Intellia ...Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceWall Street Stock Market & Finance report, prediction for the future: You'll find the Regeneron Pharmaceuticals share forecasts, stock quote and buy / sell signals below. According to present data Regeneron Pharmaceuticals's REGN shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).Find real-time GILD - Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN Business.

NTLA Stock Forecast For Tomorrow, Week, Month. SRNE Stock Forecast 2023, 2024, 2025. Intellia Therapeutics stock price predictions for March 2024. The forecast for beginning of March 27.91. Maximum value 30.29, while minimum 26.87. Averaged Intellia Therapeutics stock price for month 28.41. Price at the end 28.58, change for March 2.40%.Track Intellia Therapeutics Inc (NTLA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors The Editas Medicine stock forecast for tomorrow is $ 10.59, which would represent a 0.59% gain compared to the current price. In the next week, the price of EDIT is expected to decrease by -23.77% and hit $ 8.03. As far as the long-term Editas Medicine stock forecast is concerned, here’s what our predictions are currently suggesting. The Intellia Therapeutics stock forecast for tomorrow is $ 24.26, which would represent a 1.07% gain compared to the current price. In the next week, the price of NTLA is expected to increase by 5.31% and hit $ 25.28. As far as the long-term Intellia Therapeutics stock forecast is concerned ...In the same period, the company plans to submit an IND for NTLA-3001, its therapy for alpha-1 antitrypsin deficiency-related lung disease that's presently in early-stage trials.This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Our latest available data shows that NTLA has returned about 7.8% since the start of the ...Intellia has declined in the double digits over the past year. Superstar investor Cathie Wood is increasing her bet on a cutting-edge technology that could transform the treatment of many diseases ...

21 analysts have issued 1-year price objectives for Intellia Therapeutics' stock. Their NTLA share price targets range from $40.00 to $136.00. On average, they …

The Intellia Therapeutics stock forecast for tomorrow is $ 24.26, which would represent a 1.07% gain compared to the current price. In the next week, the price of NTLA is expected to increase by 5.31% and hit $ 25.28. As far as the long-term Intellia Therapeutics stock forecast is concerned ...Here, I discuss the central investing thesis for its fellow CRISPR/Cas9 gene-editing specialist, Intellia Therapeutics (NTLA 4.08%). This biotech growth stock, too, stands out as a potential ...Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report. To read this article on Zacks.com click ...Track Intellia Therapeutics Inc (NTLA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsBionano Genomics Inc () Stock Market info Recommendations: Buy or sell Bionano Genomics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Bionano Genomics share forecasts, stock quote and buy / sell signals below.According to present data Bionano Genomics's BNGO shares and potentially its …NTLA Pre-Market Quotes. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary ...AAPL. 189.69. -0.01%. 49.41M. View today's Intellia Therapeutics Inc stock price and latest NTLA news and analysis. Create real-time notifications to follow any changes in the live stock price.

Oct 15, 2020 · About the Intellia Therapeutics, Inc. stock forecast. As of 2023 November 30, Thursday current price of NTLA stock is 30.900$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).

View the latest Intellia Therapeutics Inc. (NTLA) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Mar 3, 2022 · Intellia Therapeutics. Market Cap. $3B. Today's Change. (-1.23%) -$0.38. Current Price. $30.65. Price as of November 27, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ... Jun 28, 2021 · Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. ... And for 2028, analysts forecast the sector to bring in revenue ... See Intellia Therapeutics, Inc. (NTLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceIntellia Therapeutics has recently been granted FDA clearance to include the United States in the global Phase 2 portion of its Phase 1/2 study for NTLA-2002. This is a significant milestone for ...Intellia Therapeutics Stock Forecast, NTLA stock price prediction. Price target in 14 days: 34.956 USD. The best long-term & short-term Intellia Therapeutics share price prognosis …Apr 18, 2023 · Analysts are bullish on NTLA stock. It currently has a mean price target of $97.19 which would be a gain of over 154% from the current price and institutional investors own approximately 85% of ... Get The Latest QCOM Stock Analysis, Price Target, Dividend Info, Headlines, Short Interest at MarketBeat. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. ... Being profitable and raising its production forecast are two reasons the Chinese EV maker Li Auto distinctly stands out from its peers Nio and Xpeng. November 13, 2023 | marketbeat ...May 4, 2023 · As for financials, the company’s top line and bottom line beat Street forecasts while its cash, cash equivalents, and marketable securities stood at $1.2B at the end of the quarter compared to ... Discover historical prices for NTLA stock on Yahoo Finance. View daily, weekly or monthly format back to when Intellia Therapeutics, Inc. stock was issued. Track Intellia Therapeutics Inc (NTLA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Stock Price Forecast. The 25 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 90.10, with a high estimate of 116.00 and a low estimate of 71.00. The ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Regeneron Pharmaceuticals share forecasts, stock quote and buy / sell signals below. According to present data Regeneron Pharmaceuticals's REGN shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).What this means: InvestorsObserver gives Intellia Therapeutics Inc. (NTLA) an overall rank of 36, which is below average. Intellia Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 36 means that 64% of stocks appear more favorable to our system.Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.Instagram:https://instagram. heritage house auctioncapital one dividendhighest monthly dividend etftrading practice sites Jul 1, 2021 · The stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days ... ea trading botbest vision insurance for seniors on medicare Intellia was founded in 2014 and went public in 2016, raising net proceeds of $112.1 million at $18 per share. The stock currently trades around $36.00 a share, translating to a market cap of $3. ... jetblue pilots On today's stock market, NTLA stock skidded 3.8%, reversing from a premarket climb and closing at 27.96. Shares of Regeneron Pharmaceuticals ( REGN ), which is collaborating with Intellia on the ...What are analysts forecasts for Intellia Therapeutics stock? The 61 analysts offering price forecasts for Intellia Therapeutics have a median target of 93.70, with a high estimate of 180.00 and a ...